[{"address1": "170 Harbor Way", "address2": "Suite 300", "city": "South San Francisco", "state": "CA", "zip": "94080", "country": "United States", "phone": "650 550 3500", "fax": "650 871 8580", "website": "https://vaxart.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Vaxart, Inc., a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; coronavirus vaccine, which is in Phase 2 clinical trial, for the treatment of SARS-CoV-2 infection; seasonal influenza vaccine, which is in Phase 2 clinical trial, to treat H1 influenza infection; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical lesions. It has a license agreement with Altesa Biosciences, Inc. to develop and commercialize Vapendavir, a capsid-binding broad-spectrum antiviral. Vaxart, Inc. is headquartered in South San Francisco, California.", "fullTimeEmployees": 109, "companyOfficers": [{"maxAge": 1, "name": "Dr. Sean N. Tucker Ph.D.", "age": 55, "title": "Senior VP & Chief Scientific Officer", "yearBorn": 1968, "fiscalYear": 2023, "totalPay": 561103, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. James F. Cummings M.D.", "age": 57, "title": "Chief Medical Officer", "yearBorn": 1966, "fiscalYear": 2023, "totalPay": 594501, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Steven  Lo", "age": 56, "title": "President, CEO & Director", "yearBorn": 1967, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Phillip Eric  Lee", "age": 35, "title": "CFO, Principal Financial Officer & Principal Accounting Officer", "yearBorn": 1988, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Raymond D. Stapleton Jr., Ph.D.", "age": 52, "title": "Chief Technology Officer", "yearBorn": 1971, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Edward B. Berg", "age": 59, "title": "Senior VP & General Counsel", "yearBorn": 1964, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Shaily Jaini Garg", "title": "Senior Vice President of Clinical Development & Project Management", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Rajesh  Kapoor Ph.D.", "title": "Senior Vice President of Quality", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 9, "boardRisk": 8, "compensationRisk": 10, "shareHolderRightsRisk": 6, "overallRisk": 9, "governanceEpochDate": 1719792000, "compensationAsOfEpochDate": 1703980800, "irWebsite": "http://newsroom.biotapharma.com/", "maxAge": 86400, "priceHint": 4, "previousClose": 0.6901, "open": 0.678, "dayLow": 0.6701, "dayHigh": 0.6892, "regularMarketPreviousClose": 0.6901, "regularMarketOpen": 0.678, "regularMarketDayLow": 0.6701, "regularMarketDayHigh": 0.6892, "exDividendDate": 1352419200, "beta": 0.651, "forwardPE": -1.3452, "volume": 854315, "regularMarketVolume": 854315, "averageVolume": 4154647, "averageVolume10days": 1984780, "averageDailyVolume10Day": 1984780, "bid": 0.6704, "ask": 0.6954, "bidSize": 200, "askSize": 1000, "marketCap": 152966048, "fiftyTwoWeekLow": 0.52, "fiftyTwoWeekHigh": 1.54, "priceToSalesTrailing12Months": 17.216213, "fiftyDayAverage": 0.7514, "twoHundredDayAverage": 0.84195, "currency": "USD", "enterpriseValue": 105990248, "floatShares": 163629980, "sharesOutstanding": 227424992, "sharesShort": 12377248, "sharesShortPriorMonth": 19996878, "sharesShortPreviousMonthDate": 1718323200, "dateShortInterest": 1721001600, "sharesPercentSharesOut": 0.0544, "heldPercentInsiders": 0.010829999, "heldPercentInstitutions": 0.23016001, "shortRatio": 1.9, "shortPercentOfFloat": 0.054899998, "impliedSharesOutstanding": 227424992, "bookValue": 0.315, "priceToBook": 2.135238, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1711843200, "netIncomeToCommon": -81742000, "trailingEps": -0.52, "forwardEps": -0.5, "lastSplitFactor": "1:11", "lastSplitDate": 1518566400, "enterpriseToRevenue": 11.929, "enterpriseToEbitda": -1.45, "52WeekChange": -0.106666684, "SandP52WeekChange": 0.19608545, "lastDividendValue": 12.188, "lastDividendDate": 1352419200, "exchange": "NCM", "quoteType": "EQUITY", "symbol": "VXRT", "underlyingSymbol": "VXRT", "shortName": "Vaxart, Inc. - Common Stock", "longName": "Vaxart, Inc.", "firstTradeDateEpochUtc": 376929000, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "4d8f7932-a203-34dc-b099-0c90a8658892", "messageBoardId": "finmb_37819645", "gmtOffSetMilliseconds": -14400000, "currentPrice": 0.6726, "targetHighPrice": 8.0, "targetLowPrice": 2.5, "targetMeanPrice": 5.25, "targetMedianPrice": 5.25, "recommendationMean": 1.7, "recommendationKey": "buy", "numberOfAnalystOpinions": 2, "totalCash": 36664000, "totalCashPerShare": 0.207, "ebitda": -73106000, "totalDebt": 23713000, "quickRatio": 2.637, "currentRatio": 3.137, "totalRevenue": 8885000, "debtToEquity": 42.58, "revenuePerShare": 0.058, "returnOnAssets": -0.46818, "returnOnEquity": -1.12404, "freeCashflow": -34376752, "operatingCashflow": -67184000, "revenueGrowth": 2.231, "operatingMargins": -11.03622, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-07-25"}]